PortfoliosLab logo
ARVN vs. KYMR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARVN and KYMR is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ARVN vs. KYMR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arvinas, Inc. (ARVN) and Kymera Therapeutics, Inc. (KYMR). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%December2025FebruaryMarchAprilMay
-73.19%
-7.49%
ARVN
KYMR

Key characteristics

Sharpe Ratio

ARVN:

-0.94

KYMR:

-0.30

Sortino Ratio

ARVN:

-1.50

KYMR:

0.01

Omega Ratio

ARVN:

0.77

KYMR:

1.00

Calmar Ratio

ARVN:

-0.84

KYMR:

-0.26

Martin Ratio

ARVN:

-1.77

KYMR:

-0.81

Ulcer Index

ARVN:

44.66%

KYMR:

24.15%

Daily Std Dev

ARVN:

84.70%

KYMR:

67.20%

Max Drawdown

ARVN:

-94.26%

KYMR:

-87.51%

Current Drawdown

ARVN:

-93.69%

KYMR:

-64.97%

Fundamentals

Market Cap

ARVN:

$556.92M

KYMR:

$2.19B

EPS

ARVN:

-$0.66

KYMR:

-$2.98

PS Ratio

ARVN:

1.30

KYMR:

46.45

PB Ratio

ARVN:

0.85

KYMR:

2.62

Total Revenue (TTM)

ARVN:

$426.90M

KYMR:

$36.79M

Gross Profit (TTM)

ARVN:

$423.60M

KYMR:

$30.91M

EBITDA (TTM)

ARVN:

-$91.00M

KYMR:

-$169.25M

Returns By Period

In the year-to-date period, ARVN achieves a -64.48% return, which is significantly lower than KYMR's -23.51% return.


ARVN

YTD

-64.48%

1M

10.02%

6M

-75.46%

1Y

-78.96%

5Y*

-33.69%

10Y*

N/A

KYMR

YTD

-23.51%

1M

46.18%

6M

-38.29%

1Y

-20.08%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARVN vs. KYMR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARVN
The Risk-Adjusted Performance Rank of ARVN is 55
Overall Rank
The Sharpe Ratio Rank of ARVN is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of ARVN is 66
Sortino Ratio Rank
The Omega Ratio Rank of ARVN is 44
Omega Ratio Rank
The Calmar Ratio Rank of ARVN is 44
Calmar Ratio Rank
The Martin Ratio Rank of ARVN is 22
Martin Ratio Rank

KYMR
The Risk-Adjusted Performance Rank of KYMR is 3636
Overall Rank
The Sharpe Ratio Rank of KYMR is 3535
Sharpe Ratio Rank
The Sortino Ratio Rank of KYMR is 3737
Sortino Ratio Rank
The Omega Ratio Rank of KYMR is 3737
Omega Ratio Rank
The Calmar Ratio Rank of KYMR is 3636
Calmar Ratio Rank
The Martin Ratio Rank of KYMR is 3434
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARVN vs. KYMR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arvinas, Inc. (ARVN) and Kymera Therapeutics, Inc. (KYMR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ARVN Sharpe Ratio is -0.94, which is lower than the KYMR Sharpe Ratio of -0.30. The chart below compares the historical Sharpe Ratios of ARVN and KYMR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00December2025FebruaryMarchAprilMay
-0.94
-0.30
ARVN
KYMR

Dividends

ARVN vs. KYMR - Dividend Comparison

Neither ARVN nor KYMR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ARVN vs. KYMR - Drawdown Comparison

The maximum ARVN drawdown since its inception was -94.26%, which is greater than KYMR's maximum drawdown of -87.51%. Use the drawdown chart below to compare losses from any high point for ARVN and KYMR. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%December2025FebruaryMarchAprilMay
-93.69%
-64.97%
ARVN
KYMR

Volatility

ARVN vs. KYMR - Volatility Comparison

Arvinas, Inc. (ARVN) has a higher volatility of 36.48% compared to Kymera Therapeutics, Inc. (KYMR) at 28.00%. This indicates that ARVN's price experiences larger fluctuations and is considered to be riskier than KYMR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%80.00%December2025FebruaryMarchAprilMay
36.48%
28.00%
ARVN
KYMR

Financials

ARVN vs. KYMR - Financials Comparison

This section allows you to compare key financial metrics between Arvinas, Inc. and Kymera Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-50.00M0.0050.00M100.00M150.00M200.00M20212022202320242025
188.80M
7.39M
(ARVN) Total Revenue
(KYMR) Total Revenue
Values in USD except per share items